Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

NCT04186819 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: rhPSMA-7.3 (18F) Injection
DIAGNOSTIC_TEST: Positron Emission Tomography scan

Sponsor

Blue Earth Diagnostics

Collaborators

[object Object]